New Mesothelioma Research Reveals Promising New Therapeutic Option
Pleural mesothelioma is a rare yet very deadly form of cancer caused by the exposure or inhalation of asbestos fibres. The cancer is particularly fatal due to the reason that it is resistant to standard cancer treatments, such as chemotherapy.
Whilst this form of cancer is more uncommon, unfortunately, cases of individuals diagnosed with mesothelioma are on the rise across some areas.
However, a new study conducted by researchers in Italy has potentially revealed a new therapeutic option which could potentially help individuals with malignant pleural mesothelioma.
This promising new therapy refers to a drug called trabectedin. In 2015, this particular drug received FDA approval for advanced sarcomas as well as ovarian cancer, yet it has now been suggested that when used in combination with a series of administered drugs, trabectedin could help to treat patients suffering from mesothelioma cancer.
Scientists from the Institute of Cancer Research at the University of Vienna tested the drug on both malignant and healthy cells, as well as on mesothelioma surgical samples.
The author of the study, Mir Alireza Hoda was quoted in Benzinga’s article saying that “Trabectedin exerted a dose-dependent cytotoxic effect in all malignant pleural mesothelioma cell cultures in vitro…,”. The author goes on to reveal that “Non-malignant mesothelial cells were significantly less responsive.”
How Does The Drug Combat Mesothelioma?
The researchers of the study explained that trabectedin helped to battle the cancer by affecting cellular expression bcl-2. Bcl-2 is a group of proteins helping to regulate apoptosis (cell death) by causing or preventing cell death.
During the investigation as the dose of trabectedin increased, the treated cancerous cells decreased.
The results of the study also saw that trabectedin was regarded as being more effective at fighting mesothelioma when it was managed with drugs which can affect cells death or when administered with cisplatin, a drug used in chemotherapy treatment.
Another element of the study included the testing of the drug on peritoneal mesothelioma tumours from mice. It was revealed that the testing of trabectedin on the tumour revealed “significant antitumor activity”.
The study assessing the effectiveness of trabectedin has certainly displayed some very interesting, important and positive results in terms of being to help treat mesothelioma cancer.
As we mentioned at the beginning of the article, as the options for effectively treating patients with mesothelioma are so limited, the results of the study have been both beneficial and promising in terms of a potential future course of treatment.
For the time being, though, trabectedin will have to undergo a lot more research and examination as it perhaps moves towards being used in mesothelioma clinical trials.
Here at Asbestos Advice Helpline, we strive to keep you updated with the most current news and updates surrounding mesothelioma, so make sure to head to our News Tab to find out more. Should you or someone you know require assistance concerning an asbestos-related disease, then please contact us here.
Posted In: Mesothelioma